On January 10, 2025, the registration application for Baiyu Ginkgolide Injection was accepted by the Ministry of Health of Azerbaijan (MOH) and entered the review stage. The product is expected to be approved for marketing before the end of 2025.

Azerbaijan is located at the junction of the Eurasian continent, with a total population of about 10.2 million. It is one of the first countries to respond to and actively participate in the joint construction of the "Belt and Road". Its pharmaceutical market also has a positive impact on other West Asian markets, laying the foundation for Baiyu to further explore other West Asian markets such as Turkey and Saudi Arabia.